|
Tumor-Associated Vasculature
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
B7-H3 expression in tumor-associated vasculature and fibroblasts was observed in the majority of samples, and endothelial B7-H3 expression was also significantly associated with poor outcome in colon cancer.
|
22473715 |
2012 |
|
tumor vasculature
|
0.050 |
AlteredExpression
|
phenotype |
BEFREE |
The aim of this study was to investigate whether a photodynamic therapy (PDT) agent that targets CD276, a receptor overexpressed in various tumor cells and tumor vasculature but with limited expression in normal tissue vasculature, could improve the tumor inhibitory efficacy of a PD-1/PD-L1 blockade.
|
30452269 |
2019 |
|
tumor vasculature
|
0.050 |
AlteredExpression
|
phenotype |
BEFREE |
In this issue of Cancer Cell, Seaman et al. demonstrate that antibody drug conjugates (ADCs) against CD276 expressed by tumor cells and tumor vasculature have promising anti-tumor activity while showing little toxicity.
|
28399405 |
2017 |
|
tumor vasculature
|
0.050 |
Biomarker
|
phenotype |
BEFREE |
Eradication of Tumors through Simultaneous Ablation of CD276/B7-H3-Positive Tumor Cells and Tumor Vasculature.
|
28399408 |
2017 |
|
tumor vasculature
|
0.050 |
Biomarker
|
phenotype |
BEFREE |
Expression and significance of B7-H3 and Tie-2 in the tumor vasculature of clear cell renal carcinoma.
|
29180874 |
2017 |
|
tumor vasculature
|
0.050 |
AlteredExpression
|
phenotype |
BEFREE |
We demonstrate that B7-H3 expression in both tumor cells and the tumor vasculature is positively associated with FOXP3+ cell number.
|
31440091 |
2019 |
|
Tumor Promotion
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Finally, we discuss the emerging roles of microRNAs (miRNAs) in inhibiting B7H3-mediated tumor promotion.
|
30035102 |
2018 |
|
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
B7-H3 associated with tumor progression and epigenetic regulatory activity in cutaneous melanoma.
|
23474948 |
2013 |
|
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
In this review, we discuss current understanding of the diverse functions of B7-H3 in carcinogenesis and cancer progression, and consider future directions for designing cancer immunotherapeutic agents targeting B7-H3.
|
24013874 |
2014 |
|
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Although numerous publications have reported the correlation between B7-H3 and cancer progression in many types of cancers, mechanistic studies on how B7-H3 regulates cancer malignancy are rare, and the mechanisms underlying the role of B7-H3 in drug resistance are almost unknown.
|
30082909 |
2019 |
|
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
In conclusion, our data present 4Ig-hB7H3 as a tumor-associated antigen and suggests a novel biological role of 4Ig-hB7H3 in tumor progression and metastasis.
|
18690846 |
2008 |
|
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
B7-H3 (B7 homologue 3, CD276) is a member of the B7 immunoregulatory family and promotes tumor progression.
|
29069741 |
2017 |
|
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
B7-H3, an immunoregulatory protein, is known to play a role in tumor progression.
|
21671471 |
2012 |
|
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
B7-H3 (CD276) belongs to the B7 family of immunoregulatory proteins and has been implicated in cancer progression and metastasis.
|
28513992 |
2017 |
|
Tumor Progression
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
B7-H3, an immunoregulatory protein, is broadly overexpressed by multiple tumor types and plays a vital role in tumor progression.
|
30952834 |
2019 |
|
Tumor Progression
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
B7 Homolog 3 (B7-H3), a newly identified member of the B7 family, is over-expressed in various human cancers and plays a vital role in tumor progression.
|
28386362 |
2017 |
|
Tumor Progression
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
B7-H3 overexpression in pancreatic cancer promotes tumor progression.
|
23242015 |
2013 |
|
Tumor Progression
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
We determined the effects of downregulating B7-H3 expression on tumor progression and the sensitivity of chemotherapeutic drug in mantle cell lymphoma.
|
25872657 |
2015 |
|
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
The exact role of B7-H3 in tumor progression and its receptor are still ambiguous.
|
29113264 |
2017 |
|
Tumor Progression
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
B7-H3 was highly expressed in human primary hepatocellular carcinoma and promoted tumor progression.
|
24787022 |
2014 |
|
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
B7-H3 is related to tumor progression in ovarian cancer.
|
28765941 |
2017 |
|
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Our results suggest that B7-H3 may be a valuable biomarker in determining tumor progression and prognosis of intrahepatic cholangiocarcinoma.
|
29696716 |
2018 |
|
Tumor Progression
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
Overexpression of B7-H3 in CD133+ colorectal cancer cells is associated with cancer progression and survival in human patients.
|
24630518 |
2014 |
|
Tumor Immunity
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
B7-H3 in tumors: friend or foe for tumor immunity?
|
29299639 |
2018 |
|
Tumor Immunity
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
In this study, we have analyzed the function of B7-H3 in tumor immunity.
|
28685773 |
2017 |